Even countries that have strong drug price negotiation schemes are only getting modest discounts for Hepatitis C drugs; they're willing to pay because even at f

Even countries that have strong drug price negotiation schemes are only getting modest discounts for Hepatitis C drugs; they're willing to pay because even at full price it's more expensive for someone to slowly die of liver failure than a course of Sovaldi that will cure them in a month. The regulatory failure is the VA system being unwilling to pay for it (assuming that's true), not the perfectly reasonably priced drug that's cheaper than alternative, less effective treatments.